BTIG Initiates Coverage On ORIC Pharmaceuticals with Buy Rating, Announces Price Target of $26

BTIG analyst Jeet Mukherjee has initiated coverage on ORIC Pharmaceuticals (NASDAQ: ORIC) with a Buy rating. The firm has set a price target of $26 for the stock.